Trial results for a study investigating a Continuous Glucose Monitor (CGM)-based advisory system in Type 1 Diabetes were posted on ClinicalTrials.gov on 2025-10-28, involving 88 participants.
Background
Type 1 Diabetes Mellitus (T1DM) is a chronic autoimmune condition requiring lifelong insulin management and careful monitoring of blood glucose levels. Maintaining optimal glycemic control is crucial to prevent both acute complications like hypoglycemia and hyperglycemia, and long-term complications affecting various organ systems. Continuous Glucose Monitoring (CGM) systems have significantly advanced diabetes management, providing real-time glucose data. The development of advisory systems that leverage CGM data aims to further optimize glycemic control by providing personalized guidance, potentially reducing the burden of self-management and improving patient outcomes. This study specifically aimed to evaluate the efficacy of such a system compared to Sensor Augmented Mode (SAM) therapy and to understand the influence of psycho-behavioral factors on its performance.
Trial design
This completed study, designated as Phase NA, enrolled 88 participants with Diabetes Mellitus, Type 1. The trial's objective was to evaluate the superior efficacy of a Continuous Glucose Monitor (CGM)-based advisory system compared to Sensor Augmented Mode (SAM) therapy. Additionally, the study aimed to characterize the impact of psycho-behavioral factors on system performance, with the goal of enabling system individualization and automated adaptation of advice delivery to optimize glycemic control and reduce the system's psychological impact.
Key results
The trial reported several key measurements related to glycemic control and hypoglycemia:
- Glycemic Outcomes (Percent of coefficient of variation):
- For the Escalation group, mean values were reported as 36.3 (Standard Deviation 4.0), 37.5 (Standard Deviation 5.3), and 38.6 (Standard Deviation 5.1).
- For the De-escalation group, mean values were reported as 35.7 (Standard Deviation 6.7), 35.8 (Standard Deviation 6.0), and 35.8 (Standard Deviation 6.6).
- Percent Time in Clinical Hypoglycemia (Percent of time):
- For the Escalation group, mean values were reported as 0.5 (Standard Deviation 0.8), 0.6 (Standard Deviation 0.6), and 0.7 (Standard Deviation 0.9).
- For the De-escalation group, mean values were reported as 0.7 (Standard Deviation 0.7), 0.6 (Standard Deviation 1.0), and 0.6 (Standard Deviation 0.9).
What this means
The posted results provide specific glycemic control metrics for participants using a CGM-based advisory system in Type 1 Diabetes, categorized into Escalation and De-escalation groups. The reported mean coefficient of variation for glycemic outcomes ranged from approximately 35.7% to 38.6% across the groups and measurements. Importantly, the mean percent time in clinical hypoglycemia remained low, ranging from 0.5% to 0.7%. While these measurements offer insights into the system's performance in managing blood glucose and minimizing hypoglycemia, the absence of comparative analyses or statistical significance values in the reported data limits the ability to draw definitive conclusions regarding the superior efficacy of the advisory system over Sensor Augmented Mode therapy, as stated in the trial's objective.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT04443153, titled "Adapting Diabetes Treatment Expert Systems to Patient in Type 1 Diabetes", were posted on 2025-10-28 on clinicaltrials.gov.